Marksans Pharma, 524404, MARKSANS Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

9,079.14
28.94
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

8,434.65
0.30%
4.40

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

11.39
13.12
10.41

EBITDA CAGR (%)

10 Years
5 Years
3 Years

11.53
20.76
-0.02

PAT CAGR (%)

10 Years
5 Years
3 Years

13.99
28.35
4.12

P:E (Median)

8 Years
5 Years
3 Years

15.43
12.28
14.12

P:BV (Average)

8 Years
5 Years
3 Years

2.73
2.46
2.56

EV:EBITDA (Average)

8 Years
5 Years
3 Years

12.60
8.21
8.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Var% Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var%
Net Sales 225.20 153.05 47.14% 241.36 172.75 39.72% 204.67 170.26 20.21% 182.04 159.15 14.38%
Expenses 191.29 130.34 46.76% 199.39 148.93 33.88% 167.37 136.49 22.62% 155.28 147.55 5.24%
EBITDA 33.91 22.71 49.32% 41.97 23.82 76.20% 37.30 33.77 10.45% 26.76 11.61 130.49%
EBIDTM 15.06% 14.84% 17.39% 13.79% 18.22% 19.84% 14.70% 7.29%
Other Income 12.19 4.30 183.49% 1.32 15.71 -91.60% 15.93 21.03 -24.25% 32.62 19.43 67.88%
Interest 0.23 0.66 -65.15% 0.27 0.85 -68.24% 0.23 1.29 -82.17% 0.26 0.82 -68.29%
Depreciation 7.47 3.51 112.82% 8.43 4.18 101.67% 8.50 4.53 87.64% 4.72 4.52 4.42%
PBT 38.40 22.84 68.13% 34.60 34.50 0.29% 44.50 48.98 -9.15% 54.40 25.70 111.67%
Tax 5.40 5.04 7.14% 9.31 8.88 4.84% 13.21 8.75 50.97% 10.20 6.50 56.92%
PAT 32.99 17.81 85.23% 25.29 25.62 -1.29% 31.29 40.23 -22.22% 44.19 19.21 130.04%
PATM 14.65% 11.64% 10.48% 14.83% 15.29% 23.63% 24.28% 12.07%
EPS 0.73 0.39 87.18% 0.56 0.57 -1.75% 0.69 0.89 -22.47% 0.98 0.42 133.33%

Description Mar 24 Mar 23 Var% Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var%
Net Sales 560.01 485.98 15.23% 586.13 479.83 22.15% 531.24 452.56 17.39% 500.03 433.77 15.28%
Expenses 450.37 376.43 19.64% 453.11 403.19 12.38% 417.29 372.30 12.08% 398.07 360.91 10.30%
EBITDA 109.64 109.55 0.08% 133.02 76.64 73.56% 113.95 80.27 41.96% 101.97 72.86 39.95%
EBIDTM 19.58% 22.54% 22.70% 15.97% 21.45% 17.74% 20.39% 16.80%
Other Income 16.53 11.01 50.14% 4.80 17.65 -72.80% 19.00 14.15 34.28% 10.10 16.50 -38.79%
Interest 4.84 2.44 98.36% 3.16 2.35 34.47% 1.63 2.54 -35.83% 1.58 1.80 -12.22%
Depreciation 21.05 13.94 51.00% 22.00 12.74 72.68% 17.55 14.05 24.91% 13.66 11.12 22.84%
PBT 100.28 104.17 -3.73% 112.66 79.20 42.25% 113.77 77.83 46.18% 96.83 76.45 26.66%
Tax 22.63 21.46 5.45% 29.69 16.90 75.68% 29.92 17.71 68.94% 26.39 16.26 62.30%
PAT 77.64 82.71 -6.13% 82.97 62.31 33.16% 83.85 60.12 39.47% 70.44 60.18 17.05%
PATM 13.86% 17.02% 14.15% 12.98% 15.78% 13.28% 14.09% 13.87%
EPS 1.73 1.81 -4.42% 1.84 1.57 17.20% 1.84 1.52 21.05% 1.52 1.46 4.11%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 853.27 655.20 658.29 599.55 433.42 424.16 294.66 215.84 358.13 405.59 314.94 Net Sales Growth 30.23% -0.47% 9.80% 38.33% 2.18% 43.95% 36.52% -39.73% -11.70% 28.78% Cost Of Goods Sold 478.93 394.44 377.59 337.91 245.41 236.34 169.35 112.37 178.18 218.16 169.63 Gross Profit 374.34 260.75 280.70 261.63 188.00 187.82 125.31 103.47 179.95 187.44 145.31 GP Margin 43.87% 39.80% 42.64% 43.64% 43.38% 44.28% 42.53% 47.94% 50.25% 46.21% 46.14% Total Expenditure 713.33 563.30 544.57 485.84 361.93 360.83 265.52 202.15 258.76 299.58 236.23 Power & Fuel Cost - 14.24 11.49 10.90 8.95 8.44 7.26 7.21 7.55 7.74 6.46 % Of Sales - 2.17% 1.75% 1.82% 2.06% 1.99% 2.46% 3.34% 2.11% 1.91% 2.05% Employee Cost - 56.09 60.46 54.64 48.51 46.33 45.86 39.77 26.13 23.65 21.39 % Of Sales - 8.56% 9.18% 9.11% 11.19% 10.92% 15.56% 18.43% 7.30% 5.83% 6.79% Manufacturing Exp. - 4.24 5.25 56.39 32.15 12.69 11.52 11.99 13.99 15.42 13.33 % Of Sales - 0.65% 0.80% 9.41% 7.42% 2.99% 3.91% 5.56% 3.91% 3.80% 4.23% General & Admin Exp. - 21.15 16.58 14.79 16.19 22.68 10.95 10.61 9.42 7.50 7.95 % Of Sales - 3.23% 2.52% 2.47% 3.74% 5.35% 3.72% 4.92% 2.63% 1.85% 2.52% Selling & Distn. Exp. - 53.97 59.37 8.56 10.37 34.30 20.58 20.20 23.48 21.52 17.46 % Of Sales - 8.24% 9.02% 1.43% 2.39% 8.09% 6.98% 9.36% 6.56% 5.31% 5.54% Miscellaneous Exp. - 19.15 13.84 2.64 0.34 0.04 0.00 0.00 0.00 5.59 17.46 % Of Sales - 2.92% 2.10% 0.44% 0.08% 0.01% 0% 0% 0% 1.38% 0% EBITDA 139.94 91.90 113.72 113.71 71.49 63.33 29.14 13.69 99.37 106.01 78.71 EBITDA Margin 16.40% 14.03% 17.28% 18.97% 16.49% 14.93% 9.89% 6.34% 27.75% 26.14% 24.99% Other Income 62.06 60.48 42.25 31.16 0.17 7.93 7.43 17.75 13.21 12.82 8.41 Interest 0.99 3.61 3.80 5.34 7.29 6.56 7.67 4.49 6.20 13.11 15.21 Depreciation 29.12 16.74 17.66 15.19 11.64 8.69 12.25 15.00 14.75 9.03 8.66 PBT 171.90 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 Tax 38.12 29.17 30.52 25.95 14.82 12.39 4.23 0.40 20.14 29.58 7.70 Tax Rate 22.18% 22.09% 22.69% 20.87% 28.11% 22.12% 25.41% 3.35% 21.98% 30.59% 12.17% PAT 133.76 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 PAT before Minority Interest 133.76 102.87 103.99 98.38 37.90 43.62 12.43 11.55 71.49 67.11 55.56 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 15.68% 15.70% 15.80% 16.41% 8.74% 10.28% 4.22% 5.35% 19.96% 16.55% 17.64% PAT Growth 30.03% -1.08% 5.70% 159.58% -13.11% 250.93% 7.62% -83.84% 6.53% 20.79% EPS 2.95 2.27 2.29 2.17 0.84 0.96 0.27 0.25 1.58 1.48 1.23

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 2,177.41 1,852.14 1,490.84 1,376.18 1,134.21 1,000.07 912.69 767.16 893.33 796.69 630.00 Net Sales Growth 17.56% 24.23% 8.33% 21.33% 13.41% 9.57% 18.97% -14.12% 12.13% 26.46% Cost Of Goods Sold 1,038.12 921.36 716.81 595.05 567.83 498.01 523.13 458.74 509.69 445.44 367.93 Gross Profit 1,139.29 930.78 774.02 781.13 566.38 502.07 389.57 308.42 383.63 351.25 262.07 GP Margin 52.32% 50.25% 51.92% 56.76% 49.94% 50.20% 42.68% 40.20% 42.94% 44.09% 41.60% Total Expenditure 1,718.84 1,512.82 1,231.96 1,036.58 941.96 867.92 834.31 734.24 760.91 620.86 516.04 Power & Fuel Cost - 24.50 18.59 16.42 14.38 14.34 11.83 13.27 12.58 9.72 7.80 % Of Sales - 1.32% 1.25% 1.19% 1.27% 1.43% 1.30% 1.73% 1.41% 1.22% 1.24% Employee Cost - 239.37 220.30 197.32 168.42 159.07 147.75 149.70 122.42 72.61 66.44 % Of Sales - 12.92% 14.78% 14.34% 14.85% 15.91% 16.19% 19.51% 13.70% 9.11% 10.55% Manufacturing Exp. - 18.73 12.73 127.47 113.32 77.14 59.90 47.34 50.44 37.59 30.11 % Of Sales - 1.01% 0.85% 9.26% 9.99% 7.71% 6.56% 6.17% 5.65% 4.72% 4.78% General & Admin Exp. - 52.58 37.74 50.67 45.52 51.03 42.51 37.52 36.01 15.35 16.13 % Of Sales - 2.84% 2.53% 3.68% 4.01% 5.10% 4.66% 4.89% 4.03% 1.93% 2.56% Selling & Distn. Exp. - 102.53 119.05 33.54 32.15 68.36 49.14 27.66 29.77 34.47 27.63 % Of Sales - 5.54% 7.99% 2.44% 2.83% 6.84% 5.38% 3.61% 3.33% 4.33% 4.39% Miscellaneous Exp. - 153.75 106.73 16.10 0.34 -0.01 0.05 0.00 0.00 5.67 27.63 % Of Sales - 8.30% 7.16% 1.17% 0.03% 0.00% 0.01% 0% 0% 0.71% 0% EBITDA 458.58 339.32 258.88 339.60 192.25 132.15 78.38 32.92 132.42 175.83 113.96 EBITDA Margin 21.06% 18.32% 17.36% 24.68% 16.95% 13.21% 8.59% 4.29% 14.82% 22.07% 18.09% Other Income 50.43 59.31 41.85 6.69 0.33 4.62 8.47 18.85 12.72 12.23 7.28 Interest 11.21 9.13 8.45 7.99 8.75 9.66 10.22 6.78 10.16 16.05 19.13 Depreciation 74.26 51.85 44.78 36.15 26.66 22.80 26.84 30.09 28.13 16.13 15.69 PBT 423.54 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 155.88 86.41 Tax 108.63 72.33 60.70 63.63 36.42 23.87 14.00 3.56 24.11 43.92 12.79 Tax Rate 25.65% 21.42% 24.52% 21.06% 23.17% 22.88% 28.11% 23.89% 22.56% 28.18% 14.80% PAT 314.90 266.31 184.56 235.94 117.02 76.46 32.94 8.83 78.51 109.39 71.90 PAT before Minority Interest 313.71 265.32 186.81 238.54 120.75 80.44 35.80 11.33 82.74 111.96 73.62 Minority Interest -1.19 0.99 -2.25 -2.60 -3.73 -3.98 -2.86 -2.50 -4.23 -2.57 -1.72 PAT Margin 14.46% 14.38% 12.38% 17.14% 10.32% 7.65% 3.61% 1.15% 8.79% 13.73% 11.41% PAT Growth 18.69% 44.29% -21.78% 101.62% 53.05% 132.12% 273.05% -88.75% -28.23% 52.14% EPS 6.95 5.88 4.07 5.21 2.58 1.69 0.73 0.19 1.73 2.41 1.59

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 1,111.32 784.67 599.72 505.63 470.57 428.97 418.88 422.70 358.18 159.92 Share Capital 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 Total Reserves 1,066.01 650.64 558.79 464.69 429.64 388.04 377.95 369.27 304.75 107.89 Non-Current Liabilities 26.48 14.41 23.93 24.79 18.39 17.09 17.30 0.31 0.50 21.68 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 12.66 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 Current Liabilities 240.91 190.39 137.26 79.73 133.39 111.22 109.59 111.19 168.43 194.83 Trade Payables 111.58 74.45 64.16 56.65 37.23 33.68 20.60 31.41 44.58 40.50 Other Current Liabilities 97.65 78.95 42.70 10.92 7.34 8.79 0.71 0.68 39.88 73.59 Short Term Borrowings 0.00 5.00 0.00 0.00 77.33 66.31 73.23 40.62 43.52 58.06 Short Term Provisions 31.68 31.99 30.40 12.15 11.50 2.45 15.04 38.49 40.45 22.68 Total Liabilities 1,378.71 989.47 760.91 610.15 622.35 557.28 545.77 534.20 527.11 376.43 Net Block 143.94 135.51 129.09 115.18 102.61 87.89 93.92 97.47 90.01 66.82 Gross Block 318.89 301.34 277.25 248.77 224.90 201.83 195.61 184.48 162.47 130.24 Accumulated Depreciation 174.95 165.83 148.16 133.59 122.28 113.94 101.69 87.01 72.45 63.42 Non Current Assets 440.58 375.75 369.32 355.73 339.98 324.78 329.16 330.16 158.45 135.93 Capital Work in Progress 3.90 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 Non Current Investment 265.75 236.07 236.07 236.07 236.07 236.07 234.29 231.44 67.62 67.62 Long Term Loans & Adv. 26.98 4.16 4.16 4.47 1.29 0.82 0.59 1.25 0.83 1.50 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 938.13 613.73 391.60 254.41 282.37 232.51 216.61 204.04 368.66 240.50 Current Investments 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 130.95 103.67 93.69 74.60 70.36 42.29 29.24 43.74 51.03 55.61 Sundry Debtors 305.49 246.78 168.93 161.87 177.83 168.87 154.80 133.41 124.63 112.38 Cash & Bank 440.26 224.05 105.61 3.35 1.80 0.71 2.56 3.13 167.54 33.37 Other Current Assets 60.88 12.06 1.91 0.82 32.38 20.62 30.01 23.76 25.46 39.14 Short Term Loans & Adv. 53.71 26.73 21.20 13.76 24.91 14.54 29.92 23.76 25.46 39.14 Net Current Assets 697.22 423.34 254.34 174.68 148.98 121.28 107.02 92.85 200.23 45.67 Total Assets 1,378.71 989.48 760.92 610.14 622.35 557.29 545.77 534.20 527.11 376.43

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 1,745.16 1,202.27 886.50 636.01 542.48 470.86 433.43 454.32 379.76 142.18 Share Capital 45.32 40.93 40.93 40.93 40.93 40.93 40.93 53.43 53.43 52.03 Total Reserves 1,699.85 1,068.24 845.56 595.08 501.55 429.93 392.50 400.89 326.33 90.15 Non-Current Liabilities 93.81 57.05 23.70 24.15 17.14 15.64 16.07 -1.91 1.46 22.16 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.82 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 12.74 1.86 2.11 1.47 1.36 1.08 0.96 0.00 0.00 0.00 Current Liabilities 365.36 380.08 298.97 228.75 232.62 234.68 296.06 259.43 286.24 319.12 Trade Payables 230.60 200.08 168.66 110.33 106.07 77.83 161.78 118.98 107.02 83.18 Other Current Liabilities 42.20 96.80 79.69 58.86 20.90 10.08 0.71 0.68 39.88 96.58 Short Term Borrowings 41.59 41.29 18.74 18.84 99.91 117.41 109.71 87.89 82.19 105.54 Short Term Provisions 50.97 41.92 31.88 40.72 5.74 29.36 23.85 51.88 57.15 33.82 Total Liabilities 2,224.24 1,660.10 1,228.03 902.02 802.46 730.73 751.81 720.20 675.56 490.10 Net Block 486.31 428.31 309.36 302.72 269.73 279.38 266.98 269.65 165.90 145.65 Gross Block 828.26 726.26 551.92 565.39 506.26 495.35 456.49 429.47 297.78 261.70 Accumulated Depreciation 341.95 297.96 242.56 262.67 236.54 215.97 189.52 159.82 131.89 116.05 Non Current Assets 524.57 435.04 325.20 308.45 271.02 280.19 267.92 280.06 166.72 147.15 Capital Work in Progress 9.87 2.57 11.68 0.00 0.00 0.00 0.36 0.00 0.00 0.00 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 28.40 4.16 4.16 5.73 1.29 0.82 0.59 10.41 0.83 1.50 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Current Assets 1,699.67 1,225.07 902.82 593.59 531.44 450.54 483.88 440.15 508.83 342.95 Current Investments 0.54 0.44 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 484.74 424.44 404.32 241.84 293.25 218.12 190.09 167.79 130.11 102.59 Sundry Debtors 416.85 394.78 271.95 243.35 176.60 176.91 247.58 217.29 183.45 169.61 Cash & Bank 714.96 349.26 212.18 93.73 33.54 39.88 25.16 35.30 185.27 46.95 Other Current Assets 82.58 24.36 14.11 11.26 28.06 15.63 21.05 19.76 10.01 23.80 Short Term Loans & Adv. 59.84 31.79 0.00 3.40 0.00 0.00 20.96 19.76 10.01 23.80 Net Current Assets 1,334.31 844.98 603.85 364.83 298.82 215.86 187.82 180.71 222.60 23.83 Total Assets 2,224.24 1,660.11 1,228.02 902.04 802.46 730.73 751.80 720.21 675.55 490.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 51.73 55.97 106.92 107.58 19.81 15.63 -13.62 64.76 112.03 54.18 PBT 132.03 134.51 124.33 52.73 56.01 16.65 11.95 91.63 96.69 63.26 Adjustment 10.91 -7.93 -8.82 19.17 11.57 20.00 12.50 8.82 17.75 14.87 Changes in Working Capital -59.60 -38.77 11.62 46.17 -34.91 -16.33 -22.39 -15.35 28.53 -15.89 Cash after chg. in Working capital 83.34 87.80 127.13 118.06 32.67 20.32 2.06 85.09 142.97 62.24 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -31.62 -31.83 -20.21 -10.49 -12.86 -4.68 -15.69 -20.33 -30.94 -8.06 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -194.62 -128.06 8.87 -24.15 -20.20 -7.55 -7.69 -177.34 -29.14 -2.01 Net Fixed Assets -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 Net Investments -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 Others -143.39 -103.79 37.61 -0.28 2.87 0.09 6.65 8.49 3.09 0.61 Cash from Financing Activity 210.02 70.86 -13.53 -81.87 0.96 -9.98 20.74 -51.83 51.28 -19.21 Net Cash Inflow / Outflow 67.12 -1.23 102.26 1.55 0.56 -1.90 -0.57 -164.41 134.17 32.96 Opening Cash & Equivalents 81.19 82.42 3.35 1.80 0.55 2.45 3.13 167.54 33.37 0.41 Closing Cash & Equivalent 148.31 81.19 105.61 3.35 1.12 0.55 2.56 3.13 167.54 33.37

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 237.41 99.26 178.59 233.33 27.40 50.09 14.06 30.80 154.51 64.84 PBT 337.65 247.51 302.16 157.17 104.31 49.80 14.90 106.85 109.40 71.91 Adjustment 74.24 35.31 56.57 42.04 31.88 43.99 26.58 39.63 24.26 19.57 Changes in Working Capital -111.47 -110.70 -131.61 59.12 -81.79 -36.23 -6.04 -88.14 20.27 -26.01 Cash after chg. in Working capital 300.43 172.12 227.12 258.33 54.40 57.56 35.44 58.34 153.94 65.47 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -63.01 -72.86 -48.53 -25.00 -27.00 -7.46 -21.37 -27.54 -0.89 -0.27 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -259.21 -84.39 -44.85 -59.58 -13.48 -38.81 -20.73 -123.01 -33.19 -4.49 Net Fixed Assets -21.45 -24.09 -28.48 -23.87 -23.07 -5.86 -11.49 -22.01 -32.23 -2.62 Net Investments -29.78 -0.18 -0.26 0.00 0.00 -1.78 -2.85 -163.82 0.00 0.00 Others -207.98 -60.12 -16.11 -35.71 9.59 -31.17 -6.39 62.82 -0.96 -1.87 Cash from Financing Activity 197.83 79.51 -15.29 -113.55 -20.78 3.38 -3.47 -57.75 16.99 -29.28 Net Cash Inflow / Outflow 176.03 94.38 118.46 60.19 -6.86 14.67 -10.14 -149.96 138.32 31.07 Opening Cash & Equivalents 206.41 112.03 93.73 33.54 39.72 25.05 35.30 185.27 46.95 15.88 Closing Cash & Equivalent 382.44 206.41 212.18 93.73 32.85 39.72 25.16 35.30 185.27 46.95

Financial Ratios

Consolidated /

Standalone

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 24.52 16.90 14.65 12.35 11.50 10.48 10.23 10.02 8.45 3.80 ROA 8.69% 11.88% 14.35% 6.15% 7.40% 2.25% 2.14% 13.47% 14.85% 16.18% ROE 11.41% 16.11% 17.80% 7.77% 9.70% 2.93% 2.79% 18.91% 27.27% 45.75% ROCE 14.27% 19.91% 23.46% 11.39% 11.99% 4.92% 3.44% 22.45% 33.41% 34.89% Fixed Asset Turnover 2.24 2.30 2.30 1.83 1.99 1.48 1.14 2.06 2.77 2.44 Receivable days 144.90 114.03 99.91 143.04 149.17 200.47 243.69 131.50 106.64 118.09 Inventory Days 61.56 54.14 50.83 61.04 48.47 44.31 61.71 48.29 47.98 61.96 Payable days 86.07 66.99 65.25 47.33 37.28 36.94 45.72 53.08 52.33 53.91 Cash Conversion Cycle 120.38 101.18 85.49 156.75 160.37 207.84 259.68 126.70 102.30 126.15 Total Debt/Equity 0.00 0.01 0.00 0.00 0.17 0.16 0.17 0.10 0.14 0.56 Interest Cover 37.54 36.44 24.26 8.23 9.54 3.17 3.66 15.77 8.37 5.16

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 38.51 27.10 21.66 15.54 13.25 11.50 10.59 10.79 8.97 3.34 ROA 13.66% 12.94% 22.40% 14.17% 10.49% 4.83% 1.54% 11.86% 19.21% 16.52% ROE 18.59% 18.72% 31.33% 20.49% 15.88% 7.92% 2.59% 20.45% 45.15% 73.02% ROCE 22.89% 23.82% 39.76% 25.57% 18.51% 10.60% 3.99% 23.16% 44.64% 38.30% Fixed Asset Turnover 2.62 2.42 2.49 2.12 2.00 1.92 1.73 2.46 2.85 2.43 Receivable days 72.63 78.56 67.57 67.57 64.51 84.88 110.59 81.87 80.88 87.17 Inventory Days 81.36 97.65 84.73 86.10 93.32 81.63 85.14 60.86 53.30 52.22 Payable days 85.31 93.88 85.57 45.09 38.48 55.10 65.56 54.58 56.06 48.85 Cash Conversion Cycle 68.67 82.33 66.73 108.58 119.35 111.40 130.17 88.15 78.13 90.54 Total Debt/Equity 0.02 0.04 0.02 0.03 0.18 0.25 0.25 0.19 0.23 1.12 Interest Cover 37.99 30.31 38.84 18.97 11.80 5.87 3.20 11.52 10.72 5.52

Top Investors:

orbimed asia iv mauritius fvci limited

massachusetts institute of technology

uti small cap fund

investor education and protection fund (iepf)

Annual Reports:

News Update:

Marksans Pharma’s arm gets marketing authorization for four products
2nd Jul 2024, 18:15 PM

The company’s arm has received marketing Authorization from UKMHRA
Read More
Marksans Pharma reports 6% fall in Q4 consolidated net profit
30th May 2024, 15:45 PM

Total consolidated income of the company increased by 16.01% at Rs 576.54 crore for Q4FY24
Read More
Marksans Pharma - Quarterly Results
30th May 2024, 12:05 PM

Read More
Marksans Pharma’s arm gets Marketing Authorisation for Levetiracetam Relonchem Oral Solution
28th May 2024, 12:24 PM

The product will be manufactured at the Group’s UK manufacturing facility
Read More

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524404 | NSE: MARKSANS

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: